PhaseBio Wins $2.8M SBIR Grant to Advance Lead Candidate

PhaseBio Pharmaceuticals said today it won a $2.8 million Fast Track Small Business Innovation Research (SBIR) grant from the NIH toward clinical development of its lead candidate PB1046 for pulmonary arterial hypertension (PAH).PB1046 is a first-in-class, sustained-release vasoactive intestinal peptide (VIP) analog already under study in an ongoing Phase I clinical trial ( NCT03315507 ).The trial, PB1046-PT-CL-000, is an open-label, dose-titration study designed to assess the safety, tolerabili